An orally delivered small-molecule formulation with antiangiogenic and anticancer activity

Vascular Biology Program and Department of Surgery, Children's Hospital Boston, Harvard Medical School, 1 Blackfan Circle, St. Karp Research Building, Boston, Massachusetts 02215, USA.
Nature Biotechnology (Impact Factor: 39.08). 08/2008; 26(7):799-807. DOI: 10.1038/nbt1415
Source: PubMed

ABSTRACT Targeting angiogenesis, the formation of blood vessels, is an important modality for cancer therapy. TNP-470, a fumagillin analog, is among the most potent and broad-spectrum angiogenesis inhibitors. However, a major clinical limitation is its poor oral availability and short half-life, necessitating frequent, continuous parenteral administration. We have addressed these issues and report an oral formulation of TNP-470, named Lodamin. TNP-470 was conjugated to monomethoxy-polyethylene glycol-polylactic acid to form nanopolymeric micelles. This conjugate can be absorbed by the intestine and selectively accumulates in tumors. Lodamin significantly inhibits tumor growth, without causing neurological impairment in tumor-bearing mice. Using the oral route of administration, it first reaches the liver, making it especially efficient in preventing the development of liver metastasis in mice. We show that Lodamin is an oral nontoxic antiangiogenic drug that can be chronically administered for cancer therapy or metastasis prevention.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Nanoparticle-based therapeutics are poised to become a leading delivery strategy for cancer treatment because they potentially offer higher selectivity, reduced toxicity, longer clearance times, and increased efficacy compared to conventional systemic therapeutic approaches. This article reviews existing nanoparticle technologies and methods that are used to target drugs to treat cancer by altering signal transduction or modulating the tumor microenvironment. We also consider the implications of recent advances in the nanotherapeutics field for the future of cancer therapy.
    Advanced drug delivery reviews 05/2014; 79-80. DOI:10.1016/j.addr.2014.05.005 · 11.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Obtustatin and Viperistatin, members of the disintegrin protein family, served as lead compounds or the synthesis of linear and cyclic peptides containing the KTS binding motif. The most active inear peptide, a Viperistatin analog, indicated the importance of Cys19 and Cys29, as well as the presence of Arg at position 24 for their biological activity, and was used as the basic sequence for the synthesis of cyclic peptides. Vimocin (Compound 6) and Vidapin (Compound 10), showed a high potency (IC50 0.17 nM) and intermediate efficacy (20% and 40%) in inhibition of adhesion of α1/α2 integrin overexpressor cells to respective collagens. Vimocin was more active in inhibition of the wound healing (53%) and corneal micropocket (17%) vascularization, while Vidapin was more potent in inhibition of migration in Matrigel tube formation assay (90%). Both compounds similarly inhibited proliferation (50-90%) of endothelial cells, and angiogenesis induced by VEGF (80%) and glioma (55%) in the chorioallantoic membrane assay. These peptides were not toxic to endothelial cell cultures and caused no acute toxicity upon iv injection in mice, and were stable for 10-30 hours in human serum. The in vitro and in vivo potency of the peptides are consistent with conformational ensembles and 'bio-active' space shared by Obtustatin and Viperistatin. These findings suggest that Vimocin and Vidapin can serve as a dual α1β1/α2β1 integrin antagonists in anti-angiogenesis and cancer therapy.
    Journal of Pharmacology and Experimental Therapeutics 06/2014; 350(3). DOI:10.1124/jpet.114.214643 · 3.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The oral route is a convenient and commonly employed way for drug delivery. However, therapeutic proteins have poor bioavailable upon oral administration due to the impermeable barrier from intestinal epithelial tight junction. Moreover, the small intestinal pH varies among different region of the intestinal tract where digestion and absorption occurs at different level. In this study, a tunable dual-emitting and pH-responsive nanocarrier that can alter the fluorescent color and emission intensity in response to pH changes and can trigger the opening of intestinal epithelial tight junction at different levels, were developed from chitosan-N-arginine and poly(γ-glutamic acid)-taurine conjugates. As pH increased from 6.0 to 8.0, the binding affinity of the oppositely charged polyions decreased, whereas the ratio of the intensity of the donor-to-acceptor emission intensity (ID/IA) increased by 27 folds. The fluorescent and pH-responsive nanocarrier that was able to monitor the pH change of intestinal environment and to control the release of an anti-angiogenic protein in response to the pH gradient. The nanocarrier triggered the opening of intestinal epithelial tight junction, consequently enhanced the permeation of the released protein through the intestinal epithelial barrier model (Caco-2 cell monolayer) to inhibit tube formation of human umbilical vein endothelial cells.
    ACS Applied Materials & Interfaces 09/2014; 6(20). DOI:10.1021/am505441p · 5.90 Impact Factor

Full-text (2 Sources)

Available from
Jun 4, 2014